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More Than Addition
The Use of Fractional Flow Reserve in
Serial Stenoses*
J. Dawn Abbott, MD
Providence, Rhode Island
Patients are often referred for cardiac catheterization based
on typical symptomatology with or without stress testing
documenting myocardial ischemia. Interventional treatment
in these cases is confounded by the finding of moderate
lesions, those with unclear hemodynamic significance based
on angiographic stenosis severity alone. Hyperemic flow
may be limited in stenoses as low as 45% diameter and other
factors, such as residual cross-sectional area, lesion length,
and collateral circulation influence resistance and flow, and
therefore, symptomatology. We also acknowledge that de-
termining the severity of coronary stenosis visually and even
quantitatively with angiography has limitations and that
stenosis severity is often visually overestimated. Although it
is reasonable to assume that a moderate stenosis is the cause
of typical exertional angina when no other identifiable
culprit is identified, the intense scrutiny our profession has
faced as well as the need to ensure we are acting in the best
interest of our patients demand that we augment angiogra-
phy with available invasive diagnostic technology in scenar-
ios of questionable revascularization appropriateness.
See page 1013
Fractional flow reserve (FFR) is a well-founded method
for determining the functional significance of a coronary
stenosis and has proven superior to angiography in guiding
percutaneous coronary intervention in single moderate le-
sions and more complicated patient subsets, including
multivessel disease (1,2). FFR is a ratio of distal coronary
pressure to mean aortic pressure and under condition of
maximal hyperemia a value lower than 0.75 to 0.80 corre-
lates with reversible ischemia on noninvasive stress testing
(3). The simple FFR ratio holds true in the case of a single
focal stenosis where vasodilation induces maximum trans-
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f this paper to disclose.stenotic flow. But how should it be interpreted in serial or
tandem stenoses?
In this issue of JACC: Cardiovascular Interventions, Kim
et al. (4) report on the clinical outcomes of 131 patients with
serial moderate stenoses treated with drug-eluting stents
(DES) using an FFR-guided approach, demonstrating the
practical application and making evident the complex phys-
iology. The study design was a prospective registry of
patients with 2 or more moderate serial stenoses within a
coronary vessel. Initially, the net effect of the lesions was
assessed and considered significant if the FFR was less than
0.8 under condition of maximal hyperemia. Next, using
pullback recordings, the stenosis that caused the largest
pressure step-up, termed the primary target lesion, was
stented first. The remaining lesion(s) were treated if, upon
reassessment, the FFR met the 0.8 threshold. Eligible
patients included those undergoing elective angiography
with serial stenosis of 40% to 70% in diameter by visual
estimate, separated by a normal segment of at least 20 mm,
and in vessels with a diameter 2 mm. All lesions were
treated with DES. Conditions that could confound FFR
measurement or clinical outcomes were appropriately ex-
cluded, such as in-stent restenosis, acute ST-segment myo-
cardial infarction, nonviable myocardium, and thrombus. In
total, 116 stents, 70 in proximal and 46 in distal lesions,
were implanted and revascularization was deferred in 61.1%
of lesions. Two or more stents were implanted in only 26
vessels (18.4%). The event rate at a median of 509 days was
low with 1 in-stent restenosis, 1 myocardial infarction, 1
noncardiac death, and no events related to deferred lesions.
The study provides further support of the validity of the
use of FFR in serial lesions first demonstrated in an animal
model and a small human study over a decade ago (5,6), but
in a larger contemporary group of patients treated with
DES. As the investigators allude, the FFR of each lesion in
tandem cannot be calculated using the equation for a single
stenosis applied to each lesion separately. The measurement
across both stenoses is valid for determination of the
contribution of both stenoses to flow; however, ignoring the
contribution of each lesion to the other will result in
underestimation of the true FFR and, therefore, of individ-
ual lesion severity. When calculating the FFR without
accounting for lesion interaction, the term “apparent FFR”
is used. The “true FFR” can only be calculated after 1
stenosis is treated or by using a more complex calculation
that takes into account the coronary wedge pressure as
described by De Bruyne et al. (5). Because obtaining a
wedge pressure requires balloon inflation, it is not practical
or recommended in a patient that otherwise has no indica-
tion for intervention. A strength of the present study is that
after treatment of the primary target lesion, the true FFR of
the nonprimary target stenosis was calculated and compared
with the apparent FFR. Similar to the original studies, the
true FFR was lower than the apparent FFR, particularly
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1020when the proximal lesion was more severe. This finding is of
critical importance and shows the influence of 1 stenosis on
the flow through a second stenosis within a vessel. The
clinical importance is that one cannot simply measure the
FFR of each lesion in isolation.
Though informative, the study has some limitations,
including the registry design and small number of patients
included. This was not a study of a physiologically guided
approach versus a standard angiographically guided ap-
proach. The number of clinical events was low; therefore, it
would be hard to justify a randomized trial where the
current strategy of FFR-guided treatment of each stenosis is
compared with stenting of all moderate lesions when a net
ischemic effect is present. In the current study, the mean
FFR after stenting was relatively low, 0.84  0.07, which
may be attributable to untreated moderate lesions or diffuse
disease as suggested by the small reference vessel diameter
(2.6  0.6 mm) reported. Studies have shown that the FFR
after stenting is predictive of outcomes. In a large registry,
an FFR of less than 0.9 after technically successful stenting
(no gradient across the stent) was observed in about one-
third of patients and was associated with higher rates of
death, MI, and repeat revascularization at 6 months com-
pared with patients with a higher FFR (7). Whether
outcomes after stenting differ based on the cause of the low
FFR, which may be due to suboptimal stent deployment,
diffuse disease, or moderate focal lesions, is unclear. An-
other concern about treating only 1 of the tandem lesions
with a DES is the influence of residual disease on the risk
for adverse events. Studies with intravascular ultrasound
have found an association between residual inflow or out-
flow disease and stent thrombosis. High-risk features in-
clude a small cross-sectional area with 70% or more plaque
burden and close proximity to the stent edge, characteristics
that were likely not present in the current study (8). This
study alleviates concern about the potential for compro-
mised inflow or outflow with a DES when not all lesions in
a coronary distribution are treated. We also must recognize
the limitations of FFR and use additional modalities when
determination of plaque morphology is indicated and apply
the practice of optimal medical therapy to all patients.
Lastly, as expected, there was poor correlation between
visual stenosis severity and functional significance and no
measured characteristics that predicted an abnormal FFR.The study adds further evidence of the utility of FFR to
augment visual estimation of coronary stenosis and guide
intervention in moderate serial lesions. Whereas the tech-
nique described is relatively simple, it requires achievement
of maximal hyperemia. We can look forward to advances in
technology that will allow hyperemia-independent measure-
ment of stenosis severity (9).
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